Ben Creelan

7.7k total citations
94 papers, 2.2k citations indexed

About

Ben Creelan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ben Creelan has authored 94 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Oncology, 51 papers in Pulmonary and Respiratory Medicine and 23 papers in Molecular Biology. Recurrent topics in Ben Creelan's work include Cancer Immunotherapy and Biomarkers (50 papers), Lung Cancer Treatments and Mutations (39 papers) and Immunotherapy and Immune Responses (17 papers). Ben Creelan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (50 papers), Lung Cancer Treatments and Mutations (39 papers) and Immunotherapy and Immune Responses (17 papers). Ben Creelan collaborates with scholars based in United States, Canada and United Kingdom. Ben Creelan's co-authors include Scott Antonia, Jhanelle E. Gray, Eric B. Haura, Tawee Tanvetyanon, Amer A. Beg, Alberto Chiappori, Anders Berglund, Steven A. Eschrich, W. Douglas Cress and Laura Q.M. Chow and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Ben Creelan

89 papers receiving 2.1k citations

Peers

Ben Creelan
Yong Wha Moon South Korea
Robert Yuan United States
Miles C. Andrews Australia
Akhil Chawla United States
Sandrine Aspeslagh Belgium
Fokhrul Hossain United States
Harper Hubbeling United States
Ji Yuan Wu United States
Luke Pike United States
Meixiao Long United States
Yong Wha Moon South Korea
Ben Creelan
Citations per year, relative to Ben Creelan Ben Creelan (= 1×) peers Yong Wha Moon

Countries citing papers authored by Ben Creelan

Since Specialization
Citations

This map shows the geographic impact of Ben Creelan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ben Creelan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ben Creelan more than expected).

Fields of papers citing papers by Ben Creelan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ben Creelan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ben Creelan. The network helps show where Ben Creelan may publish in the future.

Co-authorship network of co-authors of Ben Creelan

This figure shows the co-authorship network connecting the top 25 collaborators of Ben Creelan. A scholar is included among the top collaborators of Ben Creelan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ben Creelan. Ben Creelan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tordesillas, Leticia, Matthew Beatty, Dongliang Du, et al.. (2025). CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion. Journal for ImmunoTherapy of Cancer. 13(4). e011066–e011066. 4 indexed citations
2.
Mountzios, Giannis, Jarushka Naidoo, Chao Wang, et al.. (2024). Beyond Chemoimmunotherapy in Advanced Non–Small Cell Lung Cancer: New Frontiers, New Challenges. American Society of Clinical Oncology Educational Book. 44(3). 14 indexed citations
3.
Saltos, Andreas, Tawee Tanvetyanon, Ben Creelan, et al.. (2023). Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results.. Journal of Clinical Oncology. 41(16_suppl). 9125–9125. 2 indexed citations
4.
Thapa, Ram, Michael Shafique, Andreas Saltos, et al.. (2023). Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation. Journal of Thoracic Disease. 15(11). 6115–6125. 4 indexed citations
5.
Saltos, Andreas, Ben Creelan, Tawee Tanvetyanon, et al.. (2023). A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations. Lung Cancer. 183. 107313–107313. 3 indexed citations
6.
Alban, Tyler, Nadeem Riaz, Vlad Makarov, et al.. (2023). Abstract 1125: Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab. Cancer Research. 83(7_Supplement). 1125–1125. 1 indexed citations
7.
He, Kai, Edward B. Garon, Jorge J. Nieva, et al.. (2023). MA15.08 Multicenter Phase II Trial of LN-145 TIL Cell Therapy plus Pembrolizumab in Patients with ICI-Naïve Metastatic NSCLC. Journal of Thoracic Oncology. 18(11). S155–S155. 3 indexed citations
8.
Chiappori, Alberto, Ben Creelan, Tawee Tanvetyanon, et al.. (2022). Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 28(11). 2313–2320. 50 indexed citations
9.
Chen, Dung‐Tsa, Wenyaw Chan, Zachary Thompson, et al.. (2021). Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. PLoS ONE. 16(7). e0252041–e0252041. 4 indexed citations
10.
Innamarato, Patrick, Krithika N. Kodumudi, MacLean Hall, et al.. (2020). Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy. Molecular Therapy. 28(10). 2252–2270. 30 indexed citations
11.
Gray, Jhanelle E., Andreas Saltos, Tawee Tanvetyanon, et al.. (2019). Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 25(22). 6623–6632. 104 indexed citations
12.
Creelan, Ben & Scott Antonia. (2019). The NKG2A immune checkpoint — a new direction in cancer immunotherapy. Nature Reviews Clinical Oncology. 16(5). 277–278. 83 indexed citations
13.
Goldberg, Michael E., Meagan Montesion, Lauren Young, et al.. (2018). Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC. PLoS ONE. 13(11). e0208097–e0208097. 15 indexed citations
14.
Lam, Vincent K., David S. Hong, John V. Heymach, et al.. (2018). Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials. Annals of Oncology. 29. viii731–viii731. 2 indexed citations
15.
Creelan, Ben, Jamie K. Teer, Eric M. Toloza, et al.. (2018). OA05.03 Safety and Clinical Activity of Adoptive Cell Transfer Using Tumor Infiltrating Lymphocytes (TIL) Combined with Nivolumab in NSCLC. Journal of Thoracic Oncology. 13(10). S330–S331. 6 indexed citations
16.
Schrock, Alexa B., Viola W. Zhu, Wen-Son Hsieh, et al.. (2018). Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology. 13(9). 1312–1323. 107 indexed citations
17.
Gray, Jhanelle E., Alberto Chiappori, Tawee Tanvetyanon, et al.. (2018). A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. Cancer Immunology Immunotherapy. 67(12). 1853–1862. 29 indexed citations
18.
Smith, Matthew A., Hans‐Ulrich Schildhaus, Vincent Vuaroqueaux, et al.. (2017). MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors. Clinical Cancer Research. 23(22). 7084–7096. 11 indexed citations
19.
Antonia, Scott, et al.. (2017). Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment. Journal for ImmunoTherapy of Cancer. 5(1). 54–54. 32 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yong Wha Moon Breakdown of academic impact, for papers by Robert Yuan Breakdown of academic impact, for papers by Miles C. Andrews Breakdown of academic impact, for papers by Akhil Chawla Breakdown of academic impact, for papers by Sandrine Aspeslagh Breakdown of academic impact, for papers by Fokhrul Hossain Breakdown of academic impact, for papers by Harper Hubbeling Breakdown of academic impact, for papers by Ji Yuan Wu Breakdown of academic impact, for papers by Luke Pike Breakdown of academic impact, for papers by Meixiao Long
Rankless by CCL
2026